Johnson & Johnson (NYSE:JNJ) Gets FDA Approval

tdp2664
E money daily
Johnson & Johnson (NYSE:JNJ)'s prostate cancer drug has been approved by the U.S. FDA. Johnson & Johnson (NYSE:JNJ) Gets FDA Approval The U.S. Food and Drug Administration (FDA), has announced that they have approved Johnson & Johnson (NYSE:JNJ)'s Zytiga, in combination with prednisone, to treat patients with late-stage castration-resistant prostate cancer who have received prior chemotherapy. Johnson & Johnson (NYSE:JNJ) has signed a $1 billion deal for Cougar in 2009, the small company is developing breast cancer and multiple myeloma drugs in addition to its treatment for prostate cancer. Zytiga, an oral drug, targets a protein called cytochrome, which plays an important role in the production of testosterone. The product is designed to decrease the production of testosterone, which can stimulate cancer cell growth. Johnson & Johnson (NYSE:JNJ) company shares are currently standing at 65.38. Price History Last Price: 65.38 52 Week Low / High: 56.86 / 65.74 50 Day Moving Average: 60.25 6 Month Price Change %: 1.7% 12 Month Price Change %: 0.3%